YF17D vector based coronavirus vaccine News

|||||||||| YF17D vector based coronavirus vaccine / University of Leuven, Batavia Pharma
Preclinical, Journal: Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. (Pubmed Central) - Aug 31, 2022
Our findings warrant the development of YF-S0 as dual SARS-CoV-2 and YFV vaccine. Contrary to other viral vaccine platforms, use of YF17D does not suffer from pre-existing vector immunity.

|||||||||| YF17D vector based coronavirus vaccine / University of Leuven, Batavia Pharma
Journal: Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate. (Pubmed Central) - Mar 23, 2022
The transmission risk of YF-S0 was hence compared to readily transmitting YF-Asibi strain and non-transmitting YF17D vaccine, with no evidence for productive infection of mosquitoes. The overall favorable safety profile of YF-S0 is expected to translate to other vaccines based on the same YF17D platform.



	Diseases Companies Products Productz Mechanisms of Action Sites